Connect with us
DAPA Banner

Crypto World

Senhwa Biosciences inks up to $16M funding deal with GEM to boost AI drug discovery

Published

on

OpenAI buys tech talk show TBPN as it builds out communication strategy

Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development.

Summary

  • Senhwa Biosciences secured up to $16 million from Global Emerging Markets affiliate GEM to advance its clinical pipeline and AI-driven drug discovery platform.
  • The firm is expanding oncology programs and leveraging C2S “cell-to-sentence” technology with CellType to accelerate identification of combination cancer therapies.
  • Early AI validation supports its “cold-to-hot tumor” strategy, positioning Senhwa within the emerging immuno-oncology 2.0 space.

According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU) with GEM Yield Bahamas Limited, an affiliate of Global Emerging Markets, where the latter will provide up to $16 million in capital to support Senhwa’s strategic growth.

These include the advancement of its clinical pipeline, the expansion of its oncology programs, and the scaling of its machine learning discovery platform.

Advertisement

Besides focusing on cancer research, the firm has been looking into innovative ways to interpret complex biological datasets. After leveraging its connections with Y Combinator, it collaborated with the biotech firm CellType to implement next-generation cell-to-sentence technology.

This system has led researchers to identify actionable insights more quickly, allowing for a more structured approach to finding combination treatments for various malignancies.

The AI-enabled validation process has shown that Senhwa’s lead compounds can effectively modulate immune responses within the tumor microenvironment.

Advertisement

It reinforces its cold-to-hot tumor strategy and thus enables Senhwa to stand out as a leader in the immuno-oncology 2.0 field. This comes as AI-assisted drug discovery becomes a standard for modern medicine. For instance, the ability to predict how a drug interacts with a resistant tumor can significantly shorten the time required for clinical trials.

As per Senhwa, the strategic funding will enable it to move its clinical trials forward alongside its technological expansion. This would significantly strengthen the company’s position in the global biopharmaceutical market.

At the same time, the partnership will likely open new doors for international collaborations and future commercialization.

Advertisement

Source link

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

X Product Chief Hints at Crypto Plans, Sparks Speculation

Published

on

X Product Chief Hints at Crypto Plans, Sparks Speculation

X’s head of product Nikita Bier hinted Tuesday that the platform could launch a crypto-related product, prompting speculation across the industry.

The post drew attention because it came just weeks before the expected launch of X Money, a payments and digital wallet product that Elon Musk has presented as part of his plan to expand X into a broader financial platform.

The post quickly drew responses across the crypto industry, prompting immediate speculation around X’s potential Bitcoin (BTC) revival, Solana-related initiatives, stablecoins as well as prediction markets.

Some users also questioned whether Bier’s ties to Solana could shape how any crypto initiative at X is perceived.

Advertisement

Cointelegraph asked X for comment but had not received a response by publication.

Source: Nikita Bier

Bitcoin payments return to focus

Coinbase was among the accounts that floated Bitcoin as one possible direction, suggesting X could consider bringing the asset back into the platform’s product mix.

Though speculative, the idea echoes Bitcoin payment concepts previously explored under Twitter’s original leadership, when founder Jack Dorsey oversaw the rollout of Bitcoin tipping via the Lightning Network in 2021.

Source: Coinbase

The feature was later phased out as Twitter’s creator monetization strategy shifted following Musk’s $44 billion acquisition of the company in 2022.

X Money launch expected this month

Bier’s post came as X prepares to roll out X Money, which has been in development since Musk acquired the social media platform. The project has faced pushback from US lawmakers, including Senator Elizabeth Warren, largely over concerns about access to users’ personal financial data and broader regulatory oversight.

Source: Elon Musk

Still, Musk said in March that X Money would launch in April.

Bier’s role at Solana Foundation

Nikita Bier joined X as head of product in June 2025, months after taking on an advisory role at the Solana Foundation in March.

Advertisement

Bier said he joined the project to help “select companies launch and grow their apps,” focusing on consumer-facing mobile products built on the network.

He said Solana had reached a stage where “apps can now top the charts,” adding that his role would involve helping promising companies scale and achieve mainstream mobile adoption.

Source: Nikita Bier

Some community members have expressed skepticism about X’s potential “fix crypto” move, citing Bier’s ties to Solana.

Related: X mulls new rules for first-time crypto posts amid tortoise scam

“No clue what he’s launching, but my intuition is that it’s not good,” Pledditor wrote on X, pointing to Bier’s role at Solana.

Advertisement

Some users also noted Musk’s repeated public support for Dogecoin (DOGE), adding to skepticism around X’s plans.

Magazine: Should users be allowed to bet on war and death in prediction markets?